COST-EFFECTIVENESS OF BRODALUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS IN GREECE

被引：1
|
作者：
Solakidi, A. [1 ]
Tzanetakos, C. [1 ]
Kontodimas, S. [2 ]
Kourlaba, G. [1 ]
机构：
[1] EVROSTON LP, Athens, Greece
[2] LEO Pharma Hellas, Athens, Greece
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.09.2532
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSS32
引用
收藏
页码：S428 / S428
页数：1
相关论文
共 50 条
  • [21] COST-EFFECTIVENESS OF APREMILAST IN MODERATE TO SEVERE PSORIASIS IN SCOTLAND
    Mughal, F.
    Cawston, H.
    Kinahan, D.
    Morris, J.
    Tencer, T.
    Zhang, F.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A420 - A420
  • [22] COST-EFFECTIVENESS ANALYSIS OF SECUKINUMAB COMPARED TO CURRENT BIOLOGICS SEQUENCES FOR THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS IN FRANCE
    Duteil, E.
    Cariou, C.
    Schmidt, A.
    Benjamin, K.
    Duco, J.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A589 - A589
  • [23] The cost-effectiveness of ustekinumab for moderate-to-severe psoriasis
    Rouse, Nicole C.
    Farhangian, Michael E.
    Wehausen, Brooke
    Feldman, Steven R.
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2015, 15 (06) : 877 - 884
  • [24] ASSESSMENT OF THE COST-EFFECTIVENESS OF SECUKINUMAB VERSUS RISANKIZUMAB FOR THE TREATMENT OF ADULTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS IN THE UK
    Moreno, S.
    Walsh, S.
    Khanna, P. J.
    Jain, M.
    Tanova-Yotova, N.
    [J]. VALUE IN HEALTH, 2022, 25 (12) : S89 - S89
  • [25] COST-EFFECTIVENESS OF BIOLOGIC TREATMENTS FOR MODERATE TO SEVERE PSORIASIS
    Carretero, G.
    Moreno, J. C.
    Notario, J.
    Silvestre, J. F.
    Lopez-Belmonte, J. L.
    Gimenez, E.
    Sabater, F. J.
    Fonseca, E.
    [J]. VALUE IN HEALTH, 2009, 12 (07) : A457 - A457
  • [26] Population pharmacokinetics of brodalumab in patients with moderate to severe plaque psoriasis
    Timmermann, Stine
    Hall, Anders
    [J]. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2019, 125 (01) : 16 - 25
  • [27] COST PER RESPONDER ANALYSIS OF BRODALUMAB COMPARED WITH USTEKINUMAB IN THE TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS IN CANADA
    Schembri, J.
    Barbeau, M.
    Gaudet, V
    [J]. VALUE IN HEALTH, 2018, 21 : S425 - S425
  • [28] Effect of Prior Biologic Use on Cost-Effectiveness of Brodalumab vs. Ustekinumab for Treatment of Moderate-to-Severe Psoriasis in the United States
    Feldman, Steven R.
    Rastogi, Shipra
    Lin, Jay
    [J]. DERMATOLOGY AND THERAPY, 2018, 8 (03) : 441 - 453
  • [29] Effect of Prior Biologic Use on Cost-Effectiveness of Brodalumab vs. Ustekinumab for Treatment of Moderate-to-Severe Psoriasis in the United States
    Steven R. Feldman
    Shipra Rastogi
    Jay Lin
    [J]. Dermatology and Therapy, 2018, 8 : 441 - 453
  • [30] Cost-effectiveness of tofacitinib for the treatment of moderate to severe active ulcerative colitis in Greece
    Vellopoulou, Katerina
    Stefanou, Garyfallia
    Tzanetakos, Charalampos
    Boubouchairopoulou, Nantia
    Nakou, Magdalini
    Gourzoulidis, George
    Kourlaba, Georgia
    [J]. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2021, 33 (03) : 325 - 333
12345